The authoritative source for research information and outputs is Elsevier Scopus, with researcher profile verification from the Deanship of Scientific Research.
المخرجات
Research outputs
Articles, reviews, conference papers and book chapters, indexed by DOI and linked to University researchers.
This systematic review aimed to evaluate the prevalence, awareness, risk factors, and outcomes of preeclampsia among women in Saudi Arabia.In accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, we searched PubMed, Web of Science, and Cochrane databases, focusing on studies published between 1999 and 2024. We included observational studies conducted in Saudi Arabia reporting the risk factors, prevalence, and outcomes of preeclampsia.Overall, 21 studies were included in the analysis, of which 15 analyzed prevalence. The prevalence of preeclampsia in Saudi Arabia was 4.80%, with higher rates reported in cross-sectional studies (9.52%). Only 27% of women demonstrated preeclampsia awareness, and the key identified risk factors included serum lead, immunoglobulin A nephropathy, and calcium, magnesium, and zinc deficiencies. Adverse maternal outcomes included hemolysis, elevated liver enzymes, and low platelet syndrome and eclamptic seizures, whereas fetuses faced significant risks, including stillbirth, prematurity, and intrauterine growth restriction (IUGR).Preeclampsia poses a significant health burden in Saudi Arabia, which is compounded by limited public awareness and critical risk factors. These findings underscore the urgent need for improved preeclampsia screening and education in expectant mothers. Enhanced antenatal care and public health initiatives targeting preeclampsia awareness may improve maternal and fetal outcomes and reduce the long-term health burdens associated with this condition.
Frontiers in Pharmacology · vol. 16 · 1694803-1694803
Introduction: Osteoarthritis (OA) is a prevalent joint disorder marked by chronic inflammation and degradation of cartilage. The shielding effect of 3-O-acetyl-11-keto-β-boswellic acid (AKBA) has been confirmed in many inflammatory disorders. However, the full underlying mechanistic perspective of AKBA against OA remains unexplored. Thus, the objective of this work is to identify additional unexamined modulatory signals of AKBA against monosodium iodoacetate (MIA)-induced OA and the early prevention of irreversible cartilage damage. Methods: Male Wistar rats were allotted into three groups (n = 9): sham, MIA-OA, and MIA + AKBA250. Three mg of MIA was injected intra-articularly into the right knee joints of rats to induce OA on day 0. All treatments were given orally, daily, starting on the 3rd day after MIA injection and continuing until the 14th day of the experiment. Results: AKBA250 treatment alleviated edema completely, achieving nearly basal records of the right knee diameter. AKBA250 treatment enhanced macroscopic and microscopic findings and normalized the modified Mankin and OARSI scoring system. Moreover, AKBA restored cartilage matrix homeostasis by suppressing the catabolic enzyme matrix metalloproteinase-13 (MMP-13), upregulating tissue inhibitor of metalloproteinase-1 (TIMP-1) and the chondrogenic marker SRY-box transcription factor 9 (SOX9), and reducing the serum level of the cartilage degradation biomarker C-telopeptide of type II collagen (CTX-II). The contents of high-mobility group box 1 (HMGB1), toll-like receptor 4 (TLR4), nuclear factor-kappa B (NF-κB), and tumor necrosis factor-α (TNF-α) were substantially suppressed in the AKBA250-treated group. AKBA250 significantly boosted the nuclear factor erythroid-2-related factor 2 (Nrf2) and heme oxygenase-1 (HO-1) levels and restored the oxidant/antioxidant equilibrium disrupted by MIA. In addition, AKBA250 prominently curbed the protein expression of p-RIPK1, p-RIPK3, and p-MLKL. Furthermore, AKBA250 exhibited downregulation of miR-34a-5p and miR-146a expressions. Conclusion: Together, AKBA demonstrated a protective function in OA by inhibiting inflammatory signaling through the HMGB1/TLR4/NF-κB pathway, augmenting the cytoprotective Nrf2/HO-1 pathway, and regulating necroptosis signaling cascades.
ABSTRACT The production of saffron ( Crocus sativus L.) generates large quantities of floral by‐products, particularly stamens, which are often discarded despite their potential as sources of bioactive compounds. This study aimed to provide, for the first time, a comprehensive and comparative characterization of C. sativus stamen extracts and fractions using a multianalytical approach (UHPLC–MS/MS, GC–MS, ICP‐OES, and spectrophotometry), in order to reveal their nutritional, phytochemical, and antioxidant potential. Elemental analyses revealed high levels of essential macro‐ and micronutrients such as potassium, phosphorus, calcium, and iron. Spectrophotometric and chromatographic assays quantified sugars and proteins, while UHPLC–MS/MS and HPLC‐DAD identified key phenolic acids and flavonoids, including chlorogenic acid, rutin, quercetin, and crocin. GC–MS profiling of the petroleum ether fraction showed palmitic and oleic acids as major components. The hydrolyzed ethyl acetate fraction displayed the highest antioxidant activity across DPPH, ABTS, β‐carotene bleaching, and metal‐chelating assays, likely due to the release of aglycone phenolics and synergistic effects. This work introduces an original integrative analysis of saffron stamens, highlighting them as an underexplored and sustainable source of bioactive nutrients and antioxidants with promising applications in the food, nutraceutical, and cosmetic industries.
Libyan Journal of Medicine · vol. 20 (1) · 2585617-2585617
Metabolically dysfunction-associated steatotic liver disease (MASLD) has emerged as the leading chronic liver disease worldwide, driven primarily by metabolic derangement. The current investigation proposes to elucidate the hepatoprotective mechanisms of telmisartan (TEL) in MASLD. Twenty-four male Wistar rats were allocated to four groups (Control, MASLD, TEL-treated, and MASLD/TEL). Lipid profiles, glycemic markers, liver enzymes, and hepatic markers of oxidative stress (malondialdehyde (MDA), glutathione (GSH), superoxide dismutase (SOD), and catalase) were measured. MASLD-associated genes retrieved from GeneCards® were mapped to Rattus norvegicus ortholog genes using the gprofiler2 R package. Kyoto Encyclopedia of Genes and Genomes (KEGG) and Reactome enrichment analyses were subsequently performed using the clusterProfiler R package. Hepatic inflammatory cytokines (TNF-β, IL-6, and NF-κB), mitochondrial respiratory enzymes (Complexes I–IV), and the gene expression of Nrf2, HO-1, MMP-9, and TIMP-1 were evaluated using spectrophotometric assays for mitochondrial respiratory enzymes. Histological assessment was done using Hematoxylin and Eosin (H&E) staining, Masson's trichrome, and TGF-β immunostaining. TEL ameliorates MASLD-associated disturbances in the serum ALT level and lipid profile. It significantly reduces the levels of oxidative stress markers. KEGG and Reactome enrichment highlighted pathways involved in lipid metabolism, insulin resistance, and inflammation, with the peroxisome proliferator–activated receptor (PPAR) and AMP-activated protein kinase (AMPK) signaling pathways being the most enriched. TEL treatment increased the hepatic expression of Nrf2, HO-1, and TIMP−1 while decreasing the expression of MMP-9. The levels of the proinflammatory cytokines TNF-α and IL-6 decreased. The activities of mitochondrial enzymes (citrate synthase and complex I) improved. MASLD induced marked hepatic fibrosis, which was markedly improved following TEL treatment. TEL has notable hepatoprotective properties in MASLD by enhancing metabolic parameters, decreasing oxidative stress, and moderating inflammatory reactions.
BACKGROUND: Dupilumab is a human monoclonal antibody targeting the IL-4 receptor. There is a paucity of evidence regarding its efficacy and safety in pediatrics. Pediatric-specific data are limited, and most evidence comes from recent phase 3 trials and post hoc analyses. OBJECTIVE: To summarize the current evidence of the efficacy, safety, and biomarker effects of dupilumab in children with moderate-to-severe asthma, while identifying key gaps in the pediatric evidence base. METHODS: This study is a systematic review following PRISMA guidelines, and aims to assess the efficacy, safety, and biomarker response of dupilumab in pediatric patients with moderate to severe asthma. We evaluated the studies using the Cochrane Risk of Bias Tool 2.0. RESULTS: Six studies from 2021 to 2024 met the inclusion criteria: three of them are phase 3 randomized controlled trials and the other three post hoc analyses, mostly including children aged 6-11 years with type 2 inflammation, defined by elevated blood eosinophils and/or FeNO. Both allergic and nonallergic asthma phenotypes were represented across studies, with post hoc analyses indicating consistent benefit in each group. Dupilumab decreased the rate of severe exacerbations annually by 59.3% in children with type 2 inflammation. The study populations are mainly children between 6 and 11 years of age with moderate-to-severe asthma, characterized by eosinophilic or allergic phenotypes (type 2 asthma), including those with elevated blood eosinophils and/or FeNO levels. Dupilumab reduced the annual rate of severe exacerbation by ~59%, with greater reductions in children with FeNO ≥50 ppb (69%) or eosinophils ≥300 cells/µL (65%). The lung function showed improvement by 0.15-0.30 L in pre-bronchodilator FEV₁, accompanied by gains in asthma control and quality of life. Biomarker reductions (FeNO, eosinophils, IgE, TARC) were consistent across phenotypes. Adverse event rates were like placebo; eosinophilia and injection site reactions were more common but usually mild. CONCLUSION: This systematic review provides an early synthesis of emerging pediatric phase 3 evidence on dupilumab. While results suggest substantial benefits in reducing exacerbations, improving lung function, and modulating type 2 biomarkers, the evidence remains limited to short-term studies in a narrow age range. Longer-term follow-up, broader age representation, and real-world data are needed to define the long-term role of dupilumab in pediatric asthma. Prospero Code: CRD42024557750.
Background As a crucial cognitive and motor function, handwriting can reveal dyslexia, dysgraphia, and other neurodevelopmental conditions. With the emergence of AI, deep learning (DL) models can analyze handwriting patterns for early identification and categorization of these conditions with high level of accuracy. Objective This study presents a literature review by examining DL models in classifying learning disabilities using handwriting data. It identifies models’ shortcomings and suggests future research directions, improving model accuracy, fairness, and usability. Methodology By employing the standard literature guidelines, the authors identified 24 studies from a pool of 502 studies. They extracted dataset details, methodologies, and key findings from the studies. Findings The findings indicate the dominance of convolutional neural networks in improving learning disabilities classification through the extraction of fine-grained spatial handwritten patterns. Vision transformers (ViTs) show potential for long-range contextual feature extraction to enhance the model’s generalization capabilities. Despite these advances, dataset size, model generalizability, computational efficiency, interpretability, and real-world deployment continue to be significant challenges. Conclusions The review findings underscore the transformative potential of DL-based handwriting analysis in educational and clinical settings, providing early detection and intervention in learning disabilities.
Patient Preference and Adherence · vol. Volume 19 · 3373-3385
Background: for weight loss has surged in the Arab populations in the absence of structured real-world evaluation. Objective: To assess utilization patterns, effectiveness, and patient satisfaction with off-label Ozempic use for weight reduction across Arab populations. Methods: A cross-sectional survey was conducted using a validated bilingual questionnaire. Data included demographics, source of initiation, dose escalation, treatment duration, weight changes, and satisfaction. Analyses examined associations between demographics, treatment initiation source, dose escalation adherence, weight loss, and satisfaction. Results: Analysis included 626 users. Nearly one-third of users (30.6%) self-initiated Ozempic, most based on independent self-learning and social media. Most (72.4%) used Ozempic solely for weight reduction, with a further 20.1% for both weight loss and diabetes control. About two thirds (69.3%) started at the recommended 0.25 mg dose, significantly more often in users with physician-led initiation (p<0.05). Only 20.3% followed standard dose escalation. Of those who stopped Ozempic, 59.7% discontinued the drug early before reaching 12 weeks of use including 4 weeks at the 1.0 mg dose. Among those who discontinued, treatment duration was longer in users with physician-led initiation. Despite erratic use, reported mean weight loss by 8-12 weeks exceeded 5% in most subgroups, with no statistically significant differences across 0.25, 0.5, and 1.0 mg doses. Satisfaction, reported by 56.5% of users, was positively correlated with weight loss and shifted into the positive satisfaction level at an estimated weight reduction of 11.6%. Conclusion: Off-label Ozempic use in Arab populations is characterized by widespread self-initiation, irregular dosing, and early discontinuation. Nonetheless, clinically meaningful weight loss was achieved in many users. These findings emphasize the need for structured counseling to optimize outcomes.
Journal of Computational Biophysics and Chemistry · vol. 25 (11) · 2559-2583
A novel 2,3-dihydro-1,3,4-thiadiazole-benzenesulfonamide hybrid, N-(4-(([Formula: see text]-1-((([Formula: see text]-5-acetyl-3- (4-sulfamoylphenyl)-1,3,4-thiadiazol-2(3H)-ylidene)hydrazono)ethyl)phenyl)-4-chloro benzamide (N-ASTPC), was rationally designed as a triple inhibitor targeting carbonic anhydrase IX (CAIX), carbonic anhydrase XII (CAXII), and the epidermal growth factor receptor (EGFR) — key targets overexpressed in cancer. Molecular docking and 200-ns molecular dynamics (MD) simulations confirmed stable and high-affinity interactions of N-ASTPC with the active sites of all three targets. MM-GBSA binding free energy calculations and ProLIF interaction profiling further supported these findings, while principal component analysis (PCA) revealed limited conformational drift, indicating robust complex formation. Additionally, density functional theory (DFT) assessments affirmed N-ASTPC’s electronic stability and favorable reactivity. Biological assays demonstrated potent inhibitory activity with IC 50 values of 0.039 [Formula: see text]M, 0.04 [Formula: see text]M, and 0.05 [Formula: see text]M for CAIX, CAXII, and EGFR, respectively, comparable or superior to standard inhibitors (acetazolamide and erlotinib). Regarding in vitro cytotoxicity, N-ASTPC displayed selective toxicity toward cancer cells over normal fibroblasts, with notable effects in MDA-MB-231 and MCF-7 breast cancer lines compared to doxorubicin. Flow cytometry showed that N-ASTPC induces significant S-phase arrest and robust early apoptosis, confirmed by a [Formula: see text]5.7-fold increase in Bax, [Formula: see text]4.5-fold increase in caspase-3, and [Formula: see text]2-fold decrease in Bcl-2 expression — consistent with mitochondrial apoptotic pathway activation. Collectively, these findings establish N-ASTPC as a promising multifunctional anti-cancer lead compound capable of simultaneously disrupting tumor cell metabolism and signaling via CAIX, CAXII, and EGFR inhibition. Its multi-modal mechanism and selective apoptotic induction underscore its potential for further preclinical development, particularly in hypoxic and triple-negative breast cancer models.
carbonic anhydrase IXcarbonic anhydrase XIIepidermal growth factor receptoranticancer drug design
Background Theobromine derivatives have emerged as promising anticancer agents, but their therapeutic potential is limited by poor bioavailability. This study investigates a chitosome-based delivery system for a novel theobromine derivative, N -(4-Chlorophenyl)-2-(3,7-dimethyl-2,6-dioxo-2,3,6,7-tetrahydro-1 H -purin-1-yl)acetamide ( T-1-PCPA ), to evaluate its anticancer potential. Methods T-1-PCPA -loaded chitosomess ( T-1-PCPA loaded chitosomes) were formulated using the thin film hydration technique. Molecular docking was employed to computationally assess the stability of the T-1-PCPA loaded chitosomes. Experimentally, various physicochemical properties, including particle size, polydispersity index (PDI), zeta potential, and entrapment efficiency, were analyzed. Transmission electron microscopy (TEM) was used to investigate morphological features. In vitro , the cytotoxicity of the T-1-PCPA -PC-CS was evaluated on HCT-116 and A549 cancer cell lines. Further mechanistic studies included cell cycle analysis, apoptosis detection, and cell migration assays were performed. Results The T-1-PCPA loaded chitosomes exhibited good colloidal stability, with well-defined spherical particles averaging 142.6 ± 4.3 nm in size, a zeta potential of +32.4 ± 1.6 mV, and an entrapment efficiency of 89.2 ± 2.1%, indicating efficient drug loading and formulation stability. In vitro cytotoxicity assays revealed significantly enhanced anticancer activity, with IC 50 values of 8.05 ± 0.06 μg/mL for HCT-116 and 9.55 ± 0.15 μg/mL for A549 cells—substantially lower than those of free T-1-PCPA and blank formulations. Flow cytometric cell cycle analysis demonstrated arrest at G0-G1 and S phases, while apoptosis analysis revealed a significant increase in total apoptosis (39.55%) in treated HCT-116 cells. Cell migration assays showed a 63.4% reduction in migration compared to control, supporting the formulation's anti-migratory potential. Conclusion T-1-PCPA -loaded chitosomes system shows strong potential as a targeted anticancer nanotherapy, demonstrating enhanced cytotoxicity, apoptosis induction, cell cycle arrest, and anti-migratory activity. With high drug loading, stability, and selectivity toward cancer cells, it addresses key limitations of conventional chemotherapy. These findings warrant further preclinical evaluation for colorectal and lung cancer treatment.
chitosomestheobromine derivativesanticancer drug deliverydrug encapsulation
Archiv der Pharmazie · vol. 358 (9) · e70097-e70097
This study reports the design, synthesis, and biological evaluation of a novel series of 1,3,4-thiadiazole-based derivatives as dual B-Raf and VEGFR-2 kinase inhibitors with potential anticancer activity. Among the synthesized compounds, 7b emerged as the most potent candidate, exhibiting strong cytotoxicity against the MDA-MB-231 and MCF-7 breast cancer cell lines (IC₅₀ = 9.66 and 15.83 µM, respectively), with minimal toxicity toward normal WI-38 and WISH cells, reflected by favorable selectivity indices. Compound 7b, featuring a unique structural assembly of a 2,3-dihydro-1,3,4-thiadiazole core, a para-methoxyphenyl group, and a sulfonamide-linked methylpiperidine moiety, exhibited superior dual-inhibitory activity. It showed IC₅₀ values of 0.75 µM for B-Raf and 58.13 nM for VEGFR-2. Flow cytometry and gene expression analysis revealed that 7b induces G1-phase cell-cycle arrest and promotes apoptosis through the upregulation of BAX, caspases-8/9, and downregulation of Bcl-2. Compound 7b also inhibited cell migration in wound-healing assays. Structure-activity relationship (SAR) analysis indicated that para-substituted electron-donating groups enhanced cytotoxic potency. Molecular docking and molecular dynamics simulations confirmed the stable binding of 7b to the kinase active sites, supported by favorable Glide scores (-25.47 kcal/mol for VEGFR-2 and -31.64 kcal/mol) and MM-GBSA (molecular mechanics with generalized Born and surface area solvation) binding energies. Density functional theory (DFT) calculations further validated the compound's electronic stability and reactivity. These integrated findings suggest that compound 7b is a promising lead for further development as a selective dual kinase inhibitor for breast cancer therapy.
1,3,4-thiadiazole derivativesVEGFR-2 inhibitorsdual kinase inhibitorsbreast cancer
The pharmaceutical industry increasingly prioritizes environmental sustainability across its strategies, focusing on developing eco-friendly anti-cancer treatments. This is particularly important considering many anti-cancer drugs are not fully metabolized and pollute aquatic ecosystems. Amygdalin, a plant-derived compound, and cell-free supernatants (CFS) of Lacticaseibacillus rhamnosus show promise as sustainable anti-cancer agents. This study evaluated the potential anti-cancer activity of amygdalin and L. rhamnosus CFS against MCF-7 and A549 cancer cell lines. Cell viability was assessed using the MTT assay in response to monotherapy and combination therapy treatments. The induction of apoptosis was investigated using flow cytometric analyses. The combination demonstrated a synergistic effect on MCF-7 and A549 cell lines, with a combination index (CI) value of 0.8159 ± 0.0245 and 0.6422 ± 0.0316, respectively. Further analysis using propidium iodide (PI) staining and Annexin V confirmed increased apoptosis in combination-treated cells compared to those treated with amygdalin alone. These findings suggest that the combination of amygdalin and CFS of L. rhamnosus exhibits a synergistic anti-cancer effect against MCF-7 and A549 cells. Therefore, this combination is considered sustainable, eco-friendly, and effective anti-cancer treatment. This is the first study to investigate the anti-cancer effect of amygdalin in combination with L. rhamnosus cell-free supernatant (CFS) while considering its potential for environmental sustainability. Further research in a xenograft animal model is warranted to validate these findings.
Journal of Advanced Trends in Medical Research · vol. 2 (3) · 596-601
Background: Non-alcoholic fatty liver disease (NAFLD) is one of the causes of chronic liver diseases. Inconsistency in the microbiome population of individual guts and host–microbial interactions leads to low response in dietary and pharmacological-based treatments. This study aimed to develop and evaluate a metagenomic-guided, culturally adapted dietary and probiotic intervention to reduce hepatic fat and improve metabolic outcomes in obese Saudi adults with NAFLD. Materials and Methods: We combined gut metagenomic analysis, machine learning-based diet modelling and tailored probiotic supplementation to create an intervention platform. Probiotic specificity depends on functional deficits in bacteria participating in specific metabolic pathways, particularly bile acid metabolism. This technique supplements medication with microbiome-based drug processing. Results: At week 24, magnetic resonance imaging–proton density fat fraction (MRI-PDFF) decreased by −3.4 ± 2.2% (control), −8.9 ± 3.1% (diet) and −12.3 ± 3.8% (diet + probiotics); liver fat reduction was significant (analysis of variance (ANOVA) P = 0.0004). In the combined intervention, Faecalibacterium prausnitzii increased 2.3-fold (P = 0.003), faecal butyrate rose from 28.7 ± 4.1 to 45.2 ± 5.6 μmol/g (P = 0.002), faecal deoxycholic acid (fDCA) fell 34% (P = 0.010) with a rise in ursodeoxycholic acid (UDCA) (P = 0.015) and high-sensitivity C-reactive protein declined 42% (6.4 ± 1.7 to 3.7 ± 1.3 mg/L) versus 18% in controls (between-group P = 0.0008). Conclusion: Our precision-guided approach is a novel, scalable solution to managing NAFLD, leveraging the alignment of interactions between hosts, the microbiome and diet within a cultural context. The framework has the potential to optimise therapeutic response in high-risk Saudi communities, and the individual modulation of microbiomes on metabolic diseases is highlighted.
Journal of Infection and Public Health · vol. 18 (10) · 102873-102873
BACKGROUND: While COVID-19 has transitioned from a pandemic to an endemic state, the management of its persistent complications continues to present substantial clinical challenges. Tocilizumab, an interleukin-6 receptor antagonist endorsed by the World Health Organization (WHO) for severe COVID-19 management, remains a critical therapeutic intervention. This systematic evaluation provides a comprehensive assessment of tocilizumab's safety and efficacy profile to inform clinical decision-making. METHODS: The study involved exhaustive search across multiple databases (PubMed, SCOPUS, WoS, BIOSIS) utilizing MeSH terms and Boolean operators to identify relevant studies. Methodological worthiness was rigorously evaluated utilizing the Risk of Bias 2 (RoB 2) tool. The statistical analysis of the findings incorporated one-way ANOVA, Mann-Whitney U tests, and Pearson's correlation coefficient (r) with 95 % confidence intervals to quantify adverse effects and therapeutic outcomes. RESULTS: The analysis of nine studies encompassing diverse demographic populations (ages ≥2 years, both sexes) established a clear safety profile for tocilizumab. The treatment demonstrated a statistically important association (P < 0.05) with mild adverse effects (nausea, diarrhea, headache, fatigue; r = 0.62, 95 % CI = 0.59-0.71) and moderate adverse effects (tremors, urinary difficulties, mood changes; r = 0.54, 95 % CI = 0.47-0.60). More concerning were the severe adverse effects, including hepatobiliary dysfunction and hypersensitivity reactions (r = 0.36, 95 % CI = 0.32-0.41), with rare but critical instances of acute liver failure (r = 0.18, 95 % CI = 0.15-0.22). Notably, despite this safety profile, tocilizumab exhibited significant therapeutic efficacy (P < 0.01) in ameliorating COVID-19 symptoms, particularly in cases complicated by cytokine storm syndrome. CONCLUSION: This study confirms tocilizumab's position as a valuable therapeutic agent for COVID-19 complications while highlighting the necessity for judicious patient selection and vigilant monitoring due to its potential for significant adverse effects. The findings underscore the importance of pre-treatment screening, adherence to contraindications, and ongoing pharmacovigilance to optimize risk-benefit ratios.